1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL HUMAN MICROBIOME MARKET BY PRODUCT
5.1. Introduction
5.2. Probiotics
5.3. Prebiotics
5.4. Supplements
5.5. Others
6. GLOBAL HUMAN MICROBIOME MARKET BY DISEASE
6.1. Introduction
6.2. Diabetes
6.3. Autoimmune Disorder
6.4. Cancer
6.5. Obesity
6.6. Others
7. GLOBAL HUMAN MICROBIOME MARKET BY APPLICATION
7.1. Introduction
7.2. Diagnostics
7.3. Therapeutics
8. GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Italy
8.4.6. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Thailand
8.6.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Seres Therapeutics
10.2. Microbiome Therapeutics Innovation Group
10.3. Vedanta Biosciences Inc.
10.4. Metabiomics
10.5. Ferring Pharmaceuticals
10.6. Finch Therapeutics
10.7. BiomeBank
10.8. Biohm Technologies
10.9. Resbiotic
10.10. Immuron Limited
10.11. Maat Pharma
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES